{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:19:06Z","timestamp":1790201946368,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"am","delay-in-days":397,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.vaccine.2023.12.053","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T15:51:17Z","timestamp":1703778677000},"page":"598-607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7118-9803","authenticated-orcid":false,"given":"Albert","family":"To","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teri Ann S.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aquena H.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4684-0158","authenticated-orcid":false,"given":"Michael M.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Yalley-Ogunro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehtap","family":"Cabus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Nezami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne Andersen","family":"Elyard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoriya","family":"Borisevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystle N.","family":"Agans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4744-8560","authenticated-orcid":false,"given":"Daniel J.","family":"Deer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3389-0137","authenticated-orcid":false,"given":"Courtney","family":"Woolsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7718-1522","authenticated-orcid":false,"given":"Robert W.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Geisbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9879-3031","authenticated-orcid":false,"given":"Oreola","family":"Donini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0518-203X","authenticated-orcid":false,"given":"Axel T.","family":"Lehrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.12.053_b0005","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1473-3099(18)30791-6","article-title":"Early transmission and case fatality of Ebola virus at the index site of the 2013\u201316 west African Ebola outbreak: a cross-sectional seroprevalence survey","volume":"19","author":"Timothy","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.12.053_b0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2471\/BLT.16.171579","article-title":"Countries' response to WHO's travel recommendations during the 2013\u20132016 Ebola outbreak","volume":"95","author":"Rhymer","year":"2017","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2023.12.053_b0015","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.15585\/mmwr.mm6850a3","article-title":"Ebola Virus Disease Outbreak - Democratic Republic of the Congo, August 2018-November 2019","volume":"68","author":"Aruna","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.12.053_b0020","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1473-3099(19)30124-0","article-title":"2018 Ebola virus disease outbreak in Equateur Province, Democratic Republic of the Congo: a retrospective genomic characterisation","volume":"19","author":"Mbala-Kingebeni","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.12.053_b0025","unstructured":"Ebola Outbreak Epidemiology Team Outbreak of Ebola virus disease in the Democratic Republic of the Congo, April-May, 2018: an epidemiological study. Lancet. 2018;392:213-21."},{"key":"10.1016\/j.vaccine.2023.12.053_b0030","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1056\/NEJMoa051465","article-title":"Marburg hemorrhagic fever associated with multiple genetic lineages of virus","volume":"355","author":"Bausch","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.12.053_b0035","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1128\/JVI.00069-06","article-title":"Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola","volume":"80","author":"Towner","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.12.053_b0040","unstructured":"Repbulic of Uganda Ministry of Health Ebola Virus Disease in Uganda SitRep - 93. Uganda: World Health Organization; 2023."},{"key":"10.1016\/j.vaccine.2023.12.053_b0045","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.15585\/mmwr.mm7145a5","article-title":"Notes from the Field: Outbreak of Ebola Virus Disease Caused by Sudan ebolavirus - Uganda, August-October 2022","volume":"71","author":"Kiggundu","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"56","key":"10.1016\/j.vaccine.2023.12.053_b0050","first-page":"247","article-title":"Report of a WHO\/International Study Team","volume":"1978","author":"World Health Organization International Study Team Ebola haemorrhagic fever in Sudan","year":"1976","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2023.12.053_b0055","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1046\/j.1365-3156.2002.00944.x","article-title":"An outbreak of Ebola in Uganda","volume":"7","author":"Okware","year":"2002","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.vaccine.2023.12.053_b0060","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.12.053_b0065","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"Pollard","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.12.053_b0070","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/rmv.661","article-title":"Prospects for immunisation against Marburg and Ebola viruses","volume":"20","author":"Geisbert","year":"2010","journal-title":"Rev Med Virol"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2023.12.053_b0075","doi-asserted-by":"crossref","first-page":"S1066","DOI":"10.1093\/infdis\/jir348","article-title":"Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy","volume":"204","author":"Marzi","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.12.053_b0080","article-title":"The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigs","author":"Cao","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.vaccine.2023.12.053_b0085","article-title":"Development of Pandemic Vaccines: ERVEBO Case Study","volume":"9","author":"Wolf","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.12.053_b0090","article-title":"Natural History of Sudan ebolavirus to Support Medical Countermeasure Development","volume":"10","author":"Carbonnelle","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.12.053_b0095","unstructured":"European Medicines Agency New vaccine for prevention of Ebola virus disease recommended for approval in the European Union. ema.europa.eu; 2020."},{"key":"10.1016\/j.vaccine.2023.12.053_b0100","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41541-020-00261-9","article-title":"Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate","volume":"5","author":"Roozendaal","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2023.12.053_b0105","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1016\/j.vaccine.2017.01.068","article-title":"Recombinant proteins of Zaire ebolavirus induce potent humoral and cellular immune responses and protect against live virus infection in mice","volume":"36","author":"Lehrer","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.12.053_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.703986","article-title":"Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses","volume":"12","author":"Lehrer","year":"2021","journal-title":"Front Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2023.12.053_b0115","article-title":"Sucrose fatty acid sulphate esters as novel vaccine adjuvant","volume":"24","author":"Hilgers","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.12.053_b0120","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1016\/j.vaccine.2021.08.003","article-title":"Single-vial filovirus glycoprotein vaccines: Biophysical characteristics and immunogenicity after co-lyophilization with adjuvant","volume":"39","author":"Preston","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.12.053_b0125","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1016\/j.xphs.2022.05.017","article-title":"Lyophilized Filovirus Glycoprotein Vaccines: Peroxides in a Vaccine Formulation with Polysorbate 80-Containing Adjuvant are Associated with Reduced Neutralizing Antibody Titers in Both Mice and Non-Human Primates","volume":"111","author":"Preston","year":"2022","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2023.12.053_b0130","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/s41467-021-22132-0","article-title":"Combination therapy protects macaques against advanced Marburg virus disease","volume":"12","author":"Cross","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.12.053_b0135","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1080\/22221751.2022.2086072","article-title":"Natural history of Sudan ebolavirus infection in rhesus and cynomolgus macaques","volume":"11","author":"Woolsey","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2023.12.053_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104463","article-title":"Rapid protection of nonhuman primates against Marburg virus disease using a single low-dose VSV-based vaccine","volume":"89","author":"O'Donnell","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2023.12.053_b0145","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1016\/S2666-5247(23)00001-0","article-title":"Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques","volume":"4","author":"Marzi","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2023.12.053_b0150","doi-asserted-by":"crossref","first-page":"e0010433","DOI":"10.1371\/journal.pntd.0010433","article-title":"A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge","volume":"16","author":"Woolsey","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2023.12.053_b0155","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/14760584.2022.2053678","article-title":"Thermostable vaccines: an innovative concept in vaccine development","volume":"21","author":"Kumar","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2023.12.053_b0160","doi-asserted-by":"crossref","first-page":"6972","DOI":"10.1016\/j.vaccine.2021.10.065","article-title":"Supporting use of thermostable vaccines during public health emergencies: Considerations and recommendations for the future","volume":"39","author":"Hosangadi","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.12.053_b0165","first-page":"e0075021","article-title":"Durable Immunity to Ricin Toxin Elicited by a Thermostable","volume":"6","author":"Novak","year":"2021","journal-title":"Lyophilized Subunit Vaccine mSphere"},{"key":"10.1016\/j.vaccine.2023.12.053_b0170","first-page":"9","article-title":"Development of Thermostable Lyophilized Sabin Inactivated Poliovirus Vaccine","author":"Shin","year":"2018","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2023.12.053_b0175","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1016\/j.vaccine.2017.05.040","article-title":"A thermostable presentation of the live, attenuated peste des petits ruminants vaccine in use in Africa and Asia","volume":"35","author":"Mariner","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.12.053_b0180","first-page":"194","article-title":"Normal serum IgE and IgG antibody levels in adult male cynomolgus monkeys","volume":"38","author":"Biagini","year":"1988","journal-title":"Lab Anim Sci"},{"key":"10.1016\/j.vaccine.2023.12.053_b0185","doi-asserted-by":"crossref","first-page":"eabq6364","DOI":"10.1126\/scitranslmed.abq6364","article-title":"A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates","volume":"14","author":"Hunegnaw","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2023.12.053_b0190","doi-asserted-by":"crossref","first-page":"6054","DOI":"10.1038\/s41598-017-06226-8","article-title":"Sudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind FcgammaRI","volume":"7","author":"Radinsky","year":"2017","journal-title":"Sci Rep"},{"issue":"5593\u2013607","key":"10.1016\/j.vaccine.2023.12.053_b0195","first-page":"e18","article-title":"Pan-ebolavirus protective therapy by two multifunctional human antibodies","volume":"184","author":"Gilchuk","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2023.12.053_b0200","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/infdis\/jit162","article-title":"Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu)","volume":"208","author":"Sobarzo","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.12.053_b0205","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1038\/s41598-020-59976-3","article-title":"Immune correlates of postexposure vaccine protection against Marburg virus","volume":"10","author":"Woolsey","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.12.053_b0210","doi-asserted-by":"crossref","first-page":"S582","DOI":"10.1093\/infdis\/jiy293","article-title":"Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates","volume":"218","author":"Woolsey","year":"2018","journal-title":"J Infect Dis"},{"issue":"976\u201391","key":"10.1016\/j.vaccine.2023.12.053_b0215","first-page":"e11","article-title":"Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies","volume":"27","author":"Ilinykh","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2023.12.053_b0220","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0042-6822(03)00416-1","article-title":"Characterization of monoclonal antibodies to Marburg virus (strain Musoke) glycoprotein and identification of two protective epitopes","volume":"314","author":"Hevey","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2023.12.053_b0225","first-page":"14","article-title":"Natural History of Marburg Virus Infection to Support Medical Countermeasure Development","author":"Comer","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2023.12.053_b0230","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2023.12.053_b0235","doi-asserted-by":"crossref","first-page":"S404","DOI":"10.1086\/520591","article-title":"Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever","volume":"196","author":"Jones","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.12.053_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2021.100126","article-title":"Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice","volume":"9","author":"Lai","year":"2021","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2023.12.053_b0245","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.599587","article-title":"CoVaccine HT Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization","volume":"11","author":"Haun","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.12.053_b0250","first-page":"10","article-title":"Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels","author":"Tiemessen","year":"2022","journal-title":"Vaccines (Basel)"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23014998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23014998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:34:38Z","timestamp":1759404878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23014998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0264410X23014998"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.12.053","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.12.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}